TB006 is a monoclonal antibody targeting [Galectin-3](/proteins/galectin-3-protein) (LGALS3), a beta-galactoside-binding lectin that plays a central role in chronic neuroinflammation and the inflammaging process underlying neurodegenerative disease progression. Developed by [TrueBinding, Inc.](https://truebinding.com), TB006 is currently in a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial for [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@ctgov2025].
This trial represents a novel therapeutic approach that differs fundamentally from dopaminergic replacement strategies: rather than compensating for dopamine loss, TB006 aims to modify disease progression by resolving chronic neuroinflammation through Galectin-3 neutralization[@truebinding2025].
The trial is actively recruiting 62 participants with early-stage PD at 14 sites across the United States, with an expected completion date of March 2026[@ctgov2025].
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT06773962 |
| Phase | Phase 2a |
| Status | Recruiting |
| Study ID | TB006PD2101 |
| Sponsor | TrueBinding, Inc. |
| Start Date | March 2025 |
| Primary Completion | March 2026 |
| Enrollment | 62 participants (estimated) |
| Design | Randomized, double-blind, placebo-controlled, parallel group |
| Duration | 28 weeks |
| Route | Intravenous (IV) infusion |
TB006 is a monoclonal antibody targeting [Galectin-3](/proteins/galectin-3-protein) (LGALS3), a beta-galactoside-binding lectin that plays a central role in chronic neuroinflammation and the inflammaging process underlying neurodegenerative disease progression. Developed by [TrueBinding, Inc.](https://truebinding.com), TB006 is currently in a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial for [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@ctgov2025].
This trial represents a novel therapeutic approach that differs fundamentally from dopaminergic replacement strategies: rather than compensating for dopamine loss, TB006 aims to modify disease progression by resolving chronic neuroinflammation through Galectin-3 neutralization[@truebinding2025].
The trial is actively recruiting 62 participants with early-stage PD at 14 sites across the United States, with an expected completion date of March 2026[@ctgov2025].
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT06773962 |
| Phase | Phase 2a |
| Status | Recruiting |
| Study ID | TB006PD2101 |
| Sponsor | TrueBinding, Inc. |
| Start Date | March 2025 |
| Primary Completion | March 2026 |
| Enrollment | 62 participants (estimated) |
| Design | Randomized, double-blind, placebo-controlled, parallel group |
| Duration | 28 weeks |
| Route | Intravenous (IV) infusion |
| Arm | Type | Intervention |
|-----|------|--------------|
| TB006 | Experimental | TB006 via IV infusion |
| Placebo | Placebo Comparator | Placebo via IV infusion |
The primary objectives are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with [Parkinson's disease](/diseases/parkinsons-disease)[@ctgov2025].
(To be confirmed from full eligibility criteria — see ClinicalTrials.gov for complete list)
The inclusion of early-stage PD patients (within 5 years of diagnosis) reflects the growing recognition that neuroinflammatory processes are most active in the early disease phase when there is still substantial dopaminergic neuron survival in the [substantia nigra pars compacta](/cell-types/substantia-nigra-compacta-dopamine-neurons). Targeting inflammation at this stage may provide maximal neuroprotective benefit before significant neuronal loss has occurred.
| Site | City | State |
|------|------|-------|
| Parkinson's Research Centers of America — Orange County | Aliso Viejo | California |
| Parkinson's Research Centers of America — Palo Alto | Palo Alto | California |
| CenExel Rocky Mountain Clinical Research | Englewood | Colorado |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida |
| University of Miami | Miami | Florida |
| University of South Florida Parkinson's and Movement Disorders Center | Tampa | Florida |
| Consultants in Neurology, Ltd | Northbrook | Illinois |
| Josephson Wallack Munshower Neurology — Southeast | Indianapolis | Indiana |
| University of Kansas Medical Center | Kansas City | Kansas |
| Quest Research Institute | Farmington Hills | Michigan |
| Parkinson's Research Centers of America — Long Island | Commack | New York |
| NYU Langone Health | Patchogue | New York |
| Oregon Health & Science University | Portland | Oregon |
| Central Texas Neurology Consultants | Round Rock | Texas |
Contact: TrueBinding, Inc. — clinicaltrial@truebinding.com — 650-847-1117
[Galectin-3](/proteins/galectin-3-protein) (LGALS3) is a unique member of the galectin family distinguished by its N-terminal proline-rich domain, which enables its involvement in diverse cellular processes. In the central nervous system, Galectin-3 is primarily expressed in [microglia](/mechanisms/microglia-neuroinflammation), the brain's resident immune cells[@beraud2024].
Galectin-3 serves as a key marker of disease-associated microglia (DAM) or neurodegenerative microglia — a microglial activation state driven by chronic neuroinflammation. Elevated Galectin-3 levels have been documented in postmortem brain tissue from both [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) patients, and in CSF and blood from living patients[@joachim2024].
TB006 is a monoclonal antibody designed to neutralize Galectin-3, thereby resolving the chronic neuroinflammation characteristic of neurodegenerative disease[@truebinding2025].
Key mechanisms:
TB006's PD trial follows a Phase 1b/2a trial in [Alzheimer's disease](/diseases/alzheimers-disease), which showed improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores in patients[(@truebinding2025)]. This provides early human proof-of-concept for the anti-inflammaging approach in neurodegeneration.
TrueBinding has received FDA Expanded Access Program (EAP) authorization for TB006 in dementia including Alzheimer's disease, allowing patient access outside the clinical trial setting[(@truebinding2025)].
The fact that the same Galectin-3 targeting approach shows signals in both Alzheimer's and Parkinson's disease is significant, as it suggests chronic neuroinflammation and inflammaging may represent a shared upstream driver across multiple neurodegenerative conditions. This aligns with the growing body of evidence supporting a central role for [neuroinflammation in Alzheimer's and Parkinson's disease](/mechanisms/neuroinflammation-ad-pd) as both a cause and consequence of pathology[(@joachim2024)].
| Agent | Target | Mechanism | Trial Status |
|-------|--------|-----------|-------------|
| TB006 | Galectin-3 | mAb neutralization | Phase 2a (NCT06773962) |
| Exenatide | GLP-1R | Agonist, anti-inflammatory | Phase 3 complete |
| AMBX-0035 | NLRP3 | Small molecule inhibitor | Phase 2 planned |
| BIA 28-6156 | GBA | Small molecule | Phase 1/2 (NCT05967842) |
| Cinumercept | Nogo receptor | Fusion protein | Phase 2 (NCT04449485) |
TB006 represents one of the most direct anti-inflammatory approaches in PD, targeting a specific mediator (Galectin-3) rather than a receptor or broader inflammatory pathway. The antibody format (IV infusion) may provide advantages in CNS penetration compared to small molecules.